Dare Bioscience (DARE)
(Delayed Data from NSDQ)
$2.42 USD
+0.02 (0.83%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $2.42 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth B Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
DARE 2.42 +0.02(0.83%)
Will DARE be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for DARE based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for DARE
Is Boston Scientific (BSX) Stock Outpacing Its Medical Peers This Year?
Dare Bioscience, Inc. (DARE) Reports Q1 Loss, Lags Revenue Estimates
DARE: What are Zacks experts saying now?
Zacks Private Portfolio Services
Acadia Healthcare (ACHC) Beats Q1 Earnings Estimates
Cytek Biosciences, Inc. (CTKB) Reports Q1 Loss, Lags Revenue Estimates
Dare Bioscience, Inc. (DARE) Reports Q4 Loss, Misses Revenue Estimates
Other News for DARE
Dare Bioscience (DARE) Launches Awareness Campaign for Sildenafil Cream
Dare Bioscience, Rosy Wellness launch first phase to support DARE to PLAY
Dare Bioscience (DARE) to Host Webinar on Innovative Sildenafil Cream for Women | DARE Stock News
Dare Bioscience to host webinar on Sildenafil cream